Clinical Trials Logo

Filter by:
NCT ID: NCT06364046 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This project aims to conduct a prospective, single-center, randomized, open-label, two-arm study to compare the clinical efficacy and safety of bronchial arterial chemoembolization with drug-eluting beads (DEB-BACE) combined with serplulimab versus conventional intravenous chemotherapy combined with Serplulimab as first-line treatment for SCLC patients. The objective is to provide evidence-based support for clinical practice.

NCT ID: NCT05440890 Not yet recruiting - Clinical trials for Anterior Cruciate Ligament Injuries

Early Treatment Based Neuroscience Education in Knee

ETbNE
Start date: April 1, 2025
Phase: N/A
Study type: Interventional

Determine the effecttiveness of a cross-education strength training protocol in a group of subjects with an anterior cruciate ligament surgery.

NCT ID: NCT05509842 Not yet recruiting - Parkinson Disease Clinical Trials

Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)

Start date: April 1, 2025
Phase: N/A
Study type: Interventional

Parkinson disease (PD) is a common disorder in which reduced speed of movement results from inadequate brain production of the chemical dopamine. The most effective treatment for Parkinson disease is the use of drugs that provide dopamine replacement therapy (DRT). However, as the disease progresses there are prominent DRT-resistant features of Parkinson disease that are a major source of disability. These include cognitive (attention, memory) impairments and gait disorders such as freezing and falls. Repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, holds promise for the study and treatment of motor and cognitive deficits in persons with Parkinson's. To date, there are no conclusive results regarding an optimal rTMS protocol for recovery of motor and cognitive deficits in Parkinson's disease. This study is designed to promote clinical rehabilitation neuroscience research, and aims to improve rehabilitation in persons with Parkinson's with freezing of gait. This work will evaluate the use of a new accelerated, high dose, non-invasive brain stimulation method for treatment of freezing of gait in PD and will test how applying targeted accelerated stimulation to the brain improves gait disturbance due to PD.

NCT ID: NCT05600816 Not yet recruiting - Clinical trials for Peripheral Vascular Occlusive Disease

SurmodiCs Pounce Venous THrOMbectomy System Post Market Clinical Follow Up Study

CHOMP
Start date: April 1, 2025
Phase: N/A
Study type: Interventional

This is an open label, prospective, non-randomised, multi-centre post market study of the POUNCE Venous Thrombectomy system for de-clotting in the peripheral vasculature (e.g., iliofemoral veins).

NCT ID: NCT05612399 Not yet recruiting - Analgesia Clinical Trials

Precision Analgesia for Cardiac Surgery

Start date: April 1, 2025
Phase:
Study type: Observational

The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research. This research focuses on two of the most commonly used oral opioid analgesics, oxycodone, and methadone in elderly adults undergoing cardiac surgery.

NCT ID: NCT05673135 Not yet recruiting - Clinical trials for Hypertension in Pregnancy

The Outcomes of Hypertension in Obese Versus Non-obese Pregnant Women

Start date: April 1, 2025
Phase: N/A
Study type: Interventional

Hypertensive disorders of pregnancy, include pre-existing and gestational hypertension, preeclampsia, and eclampsia, it complicates up to 10% of pregnancies and represents a significant cause of maternal and perinatal morbidity and mortality. Following the "National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy" recommendation is currently a systolic blood pressure (SBP) ⩾ of 140 mmHg and diastolic blood pressure (DBP) ⩾ of 90 mmHg. The diagnosis generally requires two separate measurements. Accepted across international guidelines are the following four categories: Chronic/pre-existing hypertension (Hypertension discovered preconception or prior to 20 weeks gestation), Gestational hypertension (Hypertension that appears de novo after 20 weeks gestation and normalizes after pregnancy), Preeclampsia-eclampsia (De novo hypertension after 20 weeks' gestation accompanied by proteinuria, other features of maternal organ dysfunction or uteroplacental dysfunction), Chronic/pre-existing hypertension with superimposed preeclampsia-eclampsia. Over the past 2 decades, extensive epidemiologic studies have clearly established that obesity is a major risk for gestational hypertension and preeclampsia. The risk of preeclampsia typically doubles with each 5-7 kg/m2 increase in pre-pregnancy. The mechanisms have only been partially explored; increased cytokine-mediated inflammation and oxidative stress, increased shear stress, dyslipidemia, and increased sympathetic activity1 have all been proposed as possible pathways. Few studies have examined the relationship between pre-pregnancy BMI, gestational weight gain (GWG), and the risk of preeclampsia. So, our study aims to evaluate the adverse maternal and fetal outcomes related to hypertension in obese and non-obese pregnant women.

NCT ID: NCT05936229 Not yet recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Start date: April 1, 2025
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial tests the safety and how well intravenous interferon-beta-1a (FP-1201) works in preventing toxicities after CD19-directed chimeric antigen receptor (CAR) T-cell therapy in patients with B-cell cancers that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Interferon beta-1a is in a class of medications called immunomodulators. It works by protecting the lining of blood vessels, and preventing brain inflammation. Giving FP-1201 may prevent cytokine release syndrome (CRS) and immune effector cell associated-neurotoxicity syndrome (ICANS) toxicities in patients receiving CD19 CAR T-cell therapy with recurrent or refractory B-cell malignancies.

NCT ID: NCT05995574 Not yet recruiting - Communication Clinical Trials

Adolescent Contraception: Communication Training Intervention to Engage Pediatrician-Adolescent-Mother Triads

Start date: April 1, 2025
Phase: N/A
Study type: Interventional

In order to support the desire of most adolescents to delay pregnancy (parenting) until their own adulthood, pediatricians must be comfortable and skilled in having reproductive health conversations with adolescents and the mothers of adolescents. Artificial intelligence, such as a chatbot, could be programmed to simulate the perspective of the mother or the daughter as a tool for pediatricians to practice communication before interacting with "real" families. Through human-centered design, an iterative problem-solving approach, our overall goal is to develop and test a communication training chatbot tool that is accurate, developmentally tailored for adolescents and mothers, culturally tailored, and aids pediatricians to manage resistance and conflict about contraception to ultimately close disparities in teen births. The investigator's primary hypothesis is that a communication focused intervention will improve pediatrician interactions with dyads about contraception. Through three stages, the study team will develop an artificial intelligence tool as a behavioral intervention. The study team will gather basic communication data to generate, refine, modify, adapt, and pilot test novel communication tools with real-world encounters while keeping humans at the center of attention

NCT ID: NCT06151522 Not yet recruiting - Adverse Effect Clinical Trials

90% Effective Dose of Phenylephrine Infusions Under Intensive and Standard Treatment

Start date: April 1, 2025
Phase: N/A
Study type: Interventional

The objective of this study is to investigate the 90% effective dose of phenylephrine infusions for preventing postspinal anesthesia hypotension under intensive and standard treatment during cesarean section

NCT ID: NCT06158009 Not yet recruiting - Adverse Effect Clinical Trials

ED90 of Norepinephrine and Phenylephrine Boluses Under Intensive Treatment

Start date: April 1, 2025
Phase: N/A
Study type: Interventional

The objective of this study is to investigate the ED90 of norepinephrine and phenylephrine boluses for treating postspinal anesthesia hypotension under intensive treatment during cesarean section